Journal of Clinical and Aesthetic Dermatology

Psoriasis and Cutaneous Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 32 of 35

r a n d o m i z e d - d o u b l e - b l i n d - a c t i v e - a n d - p l a c e b o - controlled-phase-3-study-of-efficacy-and-safety-of- ixekizumab-adalimumab-and-placebo-therapy-in- patients-naive-to-biologic-disease-modifying-anti/. Accessed on August 22, 2016. 124. Gottlieb AB, Mease PJ, Cuchacovich RS, et al. Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). abstract/ixekizumab- improves-physical-function-quality-of-life-and-work- p r o d u c t i v i t y - i n - b i o l o g i c - d i s e a s e - m o d i f y i n g - antirheumatic-drug-naive-patients-with-active- psoriatic-arthritis/. Accessed on August 22, 2016. 125. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73(6):1020–1026. 126. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol (Hoboken, NJ). 2016;68(5):1060–1071. 127. Roubille C, Richer V, Starnino T, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the Canadian Dermatology- Rheumatology Comorbidity Initiative. J Rheumatol. 2015;42(10):1767–1780. 128. Kavanaugh A, Boyd T. Trial design in psoriatic arthritis: what could be changed? Clin Exp Rheum. 2015;33(4 Suppl 92):S15–S18. 129. Wiegell SR, Fabricius S, Stender IM, et al. A randomized, multicentre study of directed daylight exposure times of 1(1/2) vs. 2(1/2) h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp. Br J Dermatol. 2011;164(5):1083–1090. 130. Lolis MS, Marmur ES. Treatment of disseminated superficial actinic porokeratosis (DSAP) with the Q- switched ruby laser. J Cosmet Laser Ther. 2008;10(2): 124–127. 131. Bakardzhiev I, Kavaklieva S, Pehlivanov G. Successful treatment of disseminated superficial actinic porokeratosis with calcipotriol. Int J Dermatol. 2012;51(9):1139–1142. 132. Lemos BD, Storer BE, Iyer JG, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63(5):751–761. 133. Mehrany K, Otley CC, Weenig RH, et al. A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma. Dermatol Surg. 2002;28(2):113–117; discussion 117. 134. Su LD, Lowe L, Bradford CR, et al. Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol. 2002;46(5):661–666. 135. FDA. Picato (ingenol mebutate) Gel: Drug Safety Communication-FDA Warns of Severe Adverse Events, Requires Label Changes. Safety Alerts for Human Medical Products 2015. MedWatch/Safety Information/SafetyAlertsforHuman MedicalProducts/ucm459311.htm. Accessed on April 23, 2016. 136. Kircik L, Sung JC, Stein-Gold L, Goldenberg G. United States Food and Drug Administration Product Label Changes. J Clin Aesthet Dermatol. 2016;9(1):39–48. 137. Nindl I, Gottschling M, Stockfleth E. Human papillomaviruses and nonmelanoma skin cancer: basic virology and clinical manifestations. Disease Markers. 2007;23(4):247–259. 138. Nindl I, Rosl F. Molecular concepts of virus infections causing skin cancer in organ transplant recipients. Am J Transplant. 2008;8(11):2199–2204. 139. Muschik D, Braspenning-Wesch I, Stockfleth E, et al Cutaneous HPV23 E6 prevents p53 phosphorylation through interaction with HIPK2. PloS One. 2011;6(11): e27655. 140. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Pt 2):4–7. 141. Stang A, Stausberg J, Boedeker W, et al. Nationwide hospitalization costs of skin melanoma and non- melanoma skin cancer in Germany. J Eur Acad Dermatol Venereol. 2008;22(1):65–72. 142. Fernandez-Figueras MT, Carrato C, Saenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29(5):991–997. 143. Ferrandiz L, Ruiz-de-Casas A, Trakatelli M, et al. Assessing physicians' preferences on skin cancer treatment in Europe. Br J Dermatol. 2012;167(Suppl 2):29–35. 144. Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis—International League of Dermatological Societies in cooperation with the European Dermatology Forum—short version. J Eur Acad Dermatol Venereol. 2015; 29(11):2069–2079. 145. Padilla RS, Sebastian S, Jiang Z, et al. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010;146(3):288–293. 146. Stockfleth E. From a new vision of actinic keratosis to imiquimod 3.75%, the new treatment standard. Introduction. J Eur Acad Dermatol Venereol. 2015;29(Suppl 1):1–2. 147. Poulin Y, Lynde CW, Barber K, et al. Nonmelanoma skin cancer in Canada Chapter 3: Management of actinic keratoses. J Cutan Med Surg. 2015;19(3):227–238. U pdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting [ S E P T E M B E R 2 0 1 6 • V O L U M E 9 • N U M B E R 9 ] S U P P L E M E N T T O T H E J O U R N A L O F C L I N I C A L A N D A E S T H E T I C D E R M AT O L O G Y S 2 9

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Psoriasis and Cutaneous Supplement 2016